CD274 and neoplasm: On the other hand, recent evidence obtained in mouse models of different tumor types indicates that tumor-derived exosomal PD-L1 checkpoint molecules may act systemically to suppress an antitumor immune response and that this suppression may be reversed by interfering with exosomal PD-L1 release [119].